Viz.ai

Viz.ai is a healthcare AI company founded in 2016 by neurosurgeon Dr. Chris Mansi and machine learning researcher Dr. David Golan. The company provides an AI-powered care coordination platform featuring more than 50 FDA-cleared algorithms that analyze medical imaging data including CT scans, EKGs, and echocardiograms to accelerate diagnosis and treatment decisions.

The company's Viz.ai One platform serves multiple therapeutic areas including neurology, cardiology, vascular medicine, trauma, and radiology. The platform automatically detects suspected diseases in seconds and facilitates real-time communication between care teams through mobile and desktop devices. Viz.ai also operates a Life Sciences division that partners with pharmaceutical and medical device companies to develop customized solutions and support clinical trial enrollment.

The company achieved profitability in its healthcare business in 2025 while expanding its life sciences operations. Viz.ai provides 24/7 clinical specialist support and integrates with existing hospital systems to reduce delays between disease detection and treatment initiation.

Choose Viz.ai if your organization handles high volumes of time-sensitive acute care cases where minutes matter in patient outcomes. The platform excels in scenarios requiring rapid disease detection from medical imaging and immediate specialist notification, particularly for stroke, cardiac events, and vascular emergencies.

Expect a managed service approach with dedicated clinical and technical support teams. The extensive FDA clearances provide regulatory assurance, while the 24/7 support structure ensures continuous operational assistance during implementation and ongoing use.

Viz.ai is exclusively focused on healthcare, serving both provider and life sciences segments. The company's platform addresses acute care specialties including neurovascular diseases, cardiovascular conditions, vascular medicine, and trauma care. All algorithms maintain FDA clearance, demonstrating healthcare regulatory compliance.

The Life Sciences division specifically supports pharmaceutical and medical device companies with patient identification for clinical trials, adherence monitoring, and care gap closure. The platform's HIPAA-compliant architecture and Business Associate Agreement availability reflect healthcare-specific privacy and security requirements.

The ideal client is a hospital or health system with Level 1 or Level 2 trauma designation, comprehensive stroke centers, or advanced cardiac care programs handling significant acute case volumes. Organizations benefit most when they have established specialist teams requiring rapid activation and coordination across departments. Pharmaceutical and medical device companies conducting clinical trials in cardiovascular, neurovascular, or vascular disease areas also represent strong fit clients.